I think we could get there with the glaucoma division (iTrack Advance) alone. Based on peers, a $1 billion valuation for that device alone would be very realistic.
2RT is much more speculative but the potential there is enormous. Treatments for just the 10% of patients with wet AMD fetch valuations in the 10s of billions of dollars. Imagine the valuation that would be ascribed to a device that can not only treat the vast majority of patients (around 70%) but it can treat them much earlier on, thereby increasing the probability of the patient never experiencing the significant and debilitating symptoms.
Definitely very exciting stuff here and it's really starting to accelerate
Nova Eye Medical (EYE) Discussion, page-815
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $57.20M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 25.0¢ | $99.31K | 394.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 60889 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 181476 | 3 |
View Market Depth
| Last trade - 15.58pm 19/07/2024 (20 minute delay) ? |
| EYE (ASX) Chart |